PRISCILA DIB GONCALVES

(Fonte: Lattes)
Índice h a partir de 2011
10
Projetos de Pesquisa
Unidades Organizacionais
LIM/21 - Laboratório de Neuroimagem em Psiquiatria, Hospital das Clínicas, Faculdade de Medicina

Resultados de Busca

Agora exibindo 1 - 5 de 5
  • bookPart
    Reabilitação neuropsicológica
    (2021) SERAFIM, Antonio de Pádua; ROCCA, Cristiana Castanho de Almeida; GONçALVES, Priscila Dib
  • article 4 Citação(ões) na Scopus
    Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder
    (2021) CASTALDELLI-MAIA, Joao M.; MALBERGIER, Andre; OLIVEIRA, Adriana B. P. de; AMARAL, Ricardo A.; NEGRAO, Andre B.; GONCALVES, Priscila D.; VENTRIGLIO, Antonio; BERARDIS, Domenico de; ANTONIO, Juliana de; FIRIGATO, Isabela; GATTAS, Gilka J. F.; GONCALVES, Fernanda de Toledo
    Background: The efficacy of naltrexone in the treatment of alcohol use disorder (AUD) has been associated with a set of variables not directly related with the expression of opioid receptors. All the variables have been found to be highly associated with AUD itself or more severe clinical levels of AUD. Objectives: Given the high association between alcohol metabolizing enzymes (AME) and the outcome of AUD, the present study aims to investigate the role of AME genotype variants in the treatment of AUD with naltrexone. Methods: We carried out a 12-week longitudinal clinical trial based on the treatment of AUD patients with naltrexone (N = 101), stratified by different alcohol metabolization genotypes. Genotyping was performed after the inclusion of the patients in the study, based on the individual presence of single nucleotide polymorphisms (SNPs) in the ADH (alcohol dehydrogenase)1B (ADH1B*2 and ADH1B*3), ADH1C (ADHC*1) and ALDH (aldehyde dehydrogenase) 2 (ALDH2*2) genes. The outcome of alcohol use has been monitored employing the timeline follow-back during the treatment. Results: The ADH1C*1 (Ile350Val, rs698) and ALDH2*2 (Glu504Lys, rs671) polymorphisms were associated with a better response to naltrexone treatment, whereas the ADH1B*3 (Arg370Cys, rs2066702) allelic variant showed a negative outcome. Conclusions: The present study explores a genomic setting for the treatment of AUD with naltrexone. According to our findings, the association between ADH1C*1 and ALDH2*2 variants and better outcomes suggests a successful treatment, whereas the ADH1B*3 mutated allele might lead to an unsuccessful treatment. Further studies should be performed to investigate the relationship between alcohol metabolizing genotypes, the family history of alcohol use disorders and the effect of naltrexone on the outcomes. Genotyping may be a valuable tool for precision-medicine and individualized approach, especially in the context of alcohol use disorders. The small number of subjects was the main limitation of the present study.
  • article 32 Citação(ões) na Scopus
    Exploratory study on the psychological impact of COVID-19 on the general Brazilian population
    (2021) SERAFIM, Antonio P.; DURAES, Ricardo S. S.; ROCCA, Cristiana C. A.; GONCALVES, Priscila D.; SAFFI, Fabiana; CAPPELLOZZA, Alexandre; PAULINO, Mauro; DUMAS-DINIZ, Rodrigo; BRISSOS, Sofia; BRITES, Rute; ALHO, Laura; LOTUFO-NETO, Francisco
    The COVID-19 pandemic has become one of the main international concerns regarding its impact on mental health. The present study aims to investigate the prevalence of depression, anxiety, and stress symptoms, and behavioral aspects amidst the COVID-19 pandemic in a Brazilian population. An online survey was administered from May 22 to June 5, 2020 using a questionnaire comprising of sociodemographic information, the Depression, Anxiety, and Stress Scale (DASS-21), and the Coping Strategies Inventory. Participants comprised 3,000 people from Brazil's 26 states and the Federal District, with an average age of 39.8 years, women (83%), married (50.6%), graduates (70.1%) and employees (46.7%). Some contracted the virus (6.4%) and had dead friends or relatives (22.7%). There was more consumption of drugs, tobacco, medication, and food (40.8%). Almost half of participants expressed symptoms of depression (46.4%), anxiety (39.7%), and stress (42.2%). These were higher in women, people without children, students, patients with chronic diseases, and people who had contact with others diagnosed with COVID-19. The existence of a group more vulnerable to situations with a high stress burden requires greater attention regarding mental health during and after the pandemic. That said, it should be emphasized that these findings are preliminary and portray a moment still being faced by many people amid the pandemic and quarantine measures. Therefore, we understand that the magnitude of the impacts on mental health will only be more specific with continuous studies after total relaxation of the quarantine.
  • bookPart
    Transtornos relacionados ao uso de tabaco
    (2021) GONçALVES, Priscila Dib; NEGRãO, André Brooking; CASTALDELLI-MAIA, João Maurício
  • bookPart
    Tratamento dos transtornos por uso de substâncias
    (2021) MALBERGIER, André; SANCHES, Mariana Verpa; ANDRADE, Arthur Guerra de; AMARAL, Ricardo A.; NEGRãO, André Brooking; GONçALVES, Priscila Dib; CASTALDELLI-MAIA, João Maurício